Update on Pregnancy Following Breast Cancer Diagnosis and Treatment.

Abstract: Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged but might be challenging. Oncofertility counseling should be offered at the time of diagnosis to all patients, in order to inform them about the potential treatment-induced gonadotoxicity as well as the available strategies for fertility preservation, thus allowing to increase the chances of a future pregnancy. This article reports an updated overview on the current state of the art on pregnancy in women with prior breast cancer diagnosis and treatment, with a main focus on the issues faced by patients with history of hormone receptor-positive disease and BRCA carriers.
Competing Interests: Conflicts of Interest and Source of Funding: F.P. received honoraria from Eli Lilly, Novartis, and Pfizer. M.L. had advisory role for Roche, Lilly, Novartis, Astrazeneca, MSD, Exact Sciences, Seagen, Gilead, and Pfizer and received speaker honoraria from Roche, Lilly, Novartis, Pfizer, Sandoz, Libbs, Knight, and Takeda outside the submitted work. M.L. acknowledges the Italian Association for Cancer Research (“Associazione Italiana per la Ricerca sul Cancro,” AIRC; MFAG 2020 ID 24698) and the Italian Ministry of Health (5 × 1000 funds 2017) for supporting his research in the field of breast cancer in young women and oncofertility. For the remaining authors, none were declared.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)